Benzinga · Feb 26, 2026
What Drove CASI Pharmaceuticals' 24% Rise After Hours?
CASI Pharmaceuticals shares surged over 24% after hours to $0.28 despite a formal Nasdaq delisting and plans to transition to OTC Markets.
CA
NASDAQ · CASI
CASI Pharmaceuticals, Inc.
Healthcare · Biotechnology
$0.15
Up+$0.00 (+3.08%)
Updated Aug 15, 2026, 10:28 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 14.49M
- P/E ratio
- -0.3
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 7.9K
- Avg. volume
- 120.21K
Price performance
CASI price history
1M range · 0 trading sessions · Daily adjusted prices
CASI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CASI news
The latest Smart Investors Daily articles mentioning CASI.
Stock researchCompany · Overview
CASI research
Overview
Company profile and research snapshot.
Company profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2025 | HC Wainwright & Co. | Buy | — |
| May 19, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 9, 2025 | HC Wainwright & Co. | Buy | — |
| May 15, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 15, 2023 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Feb 25, 2026
Top movers in Wednesday's after hours session
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Benzinga · Feb 25, 2026
CASI Pharmaceuticals shares are trading lower after the company announced receipt of delisting decision from the Nasdaq.
Benzinga · Feb 25, 2026
Nasdaq Gains Over 1%; TJX Posts Upbeat Earnings
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
